Exploring the role and application of mitochondria in radiation therapy DOI
Yi Ding, Jing Wang,

Zhiqiang Kang

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2024, Volume and Issue: unknown, P. 167623 - 167623

Published: Dec. 1, 2024

Language: Английский

Quercetin and doxorubicin co-delivery using β-cyclodextrin nanocarrier overcomes multi-drug resistance in cancer cells via targeting Akt/NF-κB/ABCB1 signaling pathway DOI

Charan Singh Pawar,

N. Rajendra Prasad,

Priya Yadav

et al.

Emergent Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 4, 2024

Language: Английский

Citations

1
AIEgen-self-assembled nanoparticles with anti-PD-L1 antibody functionalization realize enhanced synergistic photodynamic therapy and immunotherapy against malignant melanoma DOI Creative Commons
Li Lü, Qing Xu, Xiuzhen Zhang

et al.

Materials Today Bio, Journal Year: 2024, Volume and Issue: 30, P. 101387 - 101387

Published: Dec. 6, 2024

Immune checkpoint inhibitors (ICIs) become integral in clinical practice, yet their application cancer therapy is constrained by low overall response rates and the primary resistance of cancers to ICIs. Herein, this study proposes aggregation-induced emission (AIE)-based nanoparticles (NPs) for a more effective synergistic approach combining immunotherapy photodynamic (PDT) achieve higher responses than anti-PD-L1 monotherapy. The TBP@aPD-L1 NPs are constructed functionalizing azide group-modified TBP-2 (TBP-N3) with antibodies via DBCO-S-S-PEG2000-COOH linker. target tumor cells promote TBP-N3 accumulation tumors enhanced PDT. Notably, TBP-N3, featuring emission, boosts reactive oxygen species (ROS) generation through both type I II processes TBP@aPD-L1-mediated PDT induces powerful effects direct cell-killing further elicits immunogenic cell death (ICD), which exerts anti-tumor immunity activating T ICI treatment reshapes immune microenvironment (TIME), thereby enhancing efficacy PD-L1 blockade anti-PD-L1. Consequently, demonstrated significantly inhibition growth mouse model malignant melanoma (MM). Our act as facile drug delivery platform combined treating MM.

Language: Английский

Citations

1
Simultaneous enhancement of cellular and humoral immunity by the lymph node-targeted cholesterolized TLR7 agonist liposomes DOI Creative Commons

Dandan Wan,

Ziyi Bai, Liang Yu

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(10), P. 4577 - 4590

Published: Sept. 4, 2024

Toll-like receptor (TLR) agonists, as promising adjuvants and immunotherapeutic agents, have the potential to enhance immune responses modulate antigen-dependent T-cell memory through activation of distinct signaling pathways. However, their clinical application is hindered by uncontrolled systemic inflammatory reactions. Therefore, it imperative create a vaccine adjuvant for TLR receptors that ensures both safety efficacy. In this study, we designed lymph node-targeted cholesterolized TLR7 agonist cationic liposomes (1V209-Cho-Lip

Language: Английский

Citations

0
Recent progress and current status of surface engineered magnetic nanostructures in cancer theranostics DOI

Bijaideep Dutta,

K.C. Barick, P. A. Hassan

et al.

Advances in Colloid and Interface Science, Journal Year: 2024, Volume and Issue: 334, P. 103320 - 103320

Published: Oct. 30, 2024

Language: Английский

Citations

0
Exploring the role and application of mitochondria in radiation therapy DOI
Yi Ding, Jing Wang,

Zhiqiang Kang

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2024, Volume and Issue: unknown, P. 167623 - 167623

Published: Dec. 1, 2024

Language: Английский

Citations

0